US IgA Nephropathy Pricing Strategy Model

Budesonide (Tarpeyo), sparsentan (Filspari), atrasentan (Vanrafia), iptacopan (Fabhalta) and sibeprenlimab (Voyxact) are all patient-administered and route through the Medicare Part D or commercial pharmacy benefit. Representative commercial and Part D policies condition coverage on biopsy-confirmed primary IgAN, an eGFR floor of roughly 30 mL/min/1.73m2, a proteinuria threshold typically UPCR 0.8-1.5 g/g, and a documented trial of optimized RAS blockade, increasingly alongside an SGLT2 inhibitor, before any disease-specific agent is covered. Sparsentan carries an added REMS for hepatotoxicity monitoring, enrollment friction its four competitors do not carry. Because every agent clears the same gate, the pricing lever that matters in this market is qualifying for the gate faster and more cleanly than the four incumbents already through it, not out-discounting them on net price.

This is why a conventional rebate-and-GTN waterfall does not exist for IgAN in the way it does for a crowded specialty class with active formulary competition. Budesonide's WAC runs roughly $60,000-70,000 per year and sparsentan's roughly $80,000-100,000, and the ICER 2026 assessment models cost per QALY in the $100,000-175,000 range depending on how eGFR benefit translates to ESKD delay. No disclosed rebate, net-price, or GTN figure exists for any of the five agents in the public or payer-policy record we reviewed. That absence is not a research gap to be filled with an estimate; it is the finding. A prospective entrant's pricing strategy in IgAN is a PA-qualification strategy first, built around confirmatory eGFR-slope evidence and REMS-free administration, with the WAC-to-ICER math as a secondary check rather than a rebate negotiation to be modeled line by line.

Every AXLRx pricing model is built from primary regulatory and payer-policy sources, not secondary summaries. Where a rebate or net-price figure is not disclosed anywhere in the primary record, the model states that gap explicitly rather than substituting an estimate.

IgA nephropathy US pricing sources: FDA Drugs@FDA and product labeling for approval status, routing and the sparsentan REMS; representative commercial and Medicare Part D specialty pharmacy prior-authorization policies; the ICER 2026 IgA nephropathy assessment and CTAF review.